Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patientsKINEKAWA, Fumihiko; KUBO, Fumiyoshi; KURIYAMA, Shigeki et al.Hepato-gastroenterology. 2005, Vol 52, Num 62, pp 471-474, issn 0172-6390, 4 p.Article

Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophilsSUZUKI, K; KAWAMURA, T; SAKAKIBARA, F et al.Diabetic medicine. 1999, Vol 16, Num 1, pp 67-73, issn 0742-3071Article

Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients : Role of the polyol pathwayTSUKUSHI, S; KATSUZAKI, T; AOYAMA, I et al.Kidney international. 1999, Vol 55, Num 5, pp 1970-1976, issn 0085-2538Conference Paper

Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patientsASANO, Tomoichiro; SAITO, Yasushi; KAWAKAMI, Masanobu et al.Journal of diabetes and its complications. 2002, Vol 16, Num 2, pp 133-138, issn 1056-8727Article

Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogsKUBO, E; MORI, K; KOBAYASHI, T et al.Journal of ocular pharmacology and therapeutics. 1998, Vol 14, Num 2, pp 181-190, issn 1080-7683Article

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trialHOTTA, Nigishi; AKANUMA, Yasuo; SHIGETA, Yukio et al.Diabetes care. 2006, Vol 29, Num 7, pp 1538-1544, issn 0149-5992, 7 p.Article

Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patientsSATO, N; KASHIMA, K; UEHARA, Y et al.Diabetes care. 1997, Vol 20, Num 6, pp 995-998, issn 0149-5992Article

Epalrestat, an aldose reductase inhibitor, reduces the levels of N^ε-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patientsHAMADA, Yoji; NAKAMURA, Jiro; NARUSE, Keiko et al.Diabetes care. 2000, Vol 23, Num 10, pp 1539-1544, issn 0149-5992Article

I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapyUTSUNOMIYA, K; NARABAYASHI, I; NAKATANI, Y et al.Clinical nuclear medicine. 1999, Vol 24, Num 6, pp 418-420, issn 0363-9762Article

Three-Component, One-Flask Synthesis of Rhodanines (Thiazolidinones)JACOBINE, Alexander M; POSNER, Gary H.Journal of organic chemistry. 2011, Vol 76, Num 19, pp 8121-8125, issn 0022-3263, 5 p.Article

The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic ratsSASAKI, H; NAKA, K; KISHI, Y et al.Experimental neurology (Print). 1997, Vol 146, Num 2, pp 466-470, issn 0014-4886Article

Polyol pathway and protein kinase C activity of rat Schwannoma cellsKAMIYA, Hideki; NAKAMURA, Jiro; HAMADA, Yoji et al.Diabetes/metabolism research and reviews (Print). 2003, Vol 19, Num 2, pp 131-139, issn 1520-7552, 9 p.Article

Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathyNAKAYAMA, Mikihiro; NAKAMURA, Jiro; HAMADA, Yoji et al.Diabetes care. 2001, Vol 24, Num 6, pp 1093-1098, issn 0149-5992Article

Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance testsKAMON, N; MABUCHI, H; TAKEDA, R et al.Hormone and metabolic research. 1991, Vol 23, Num 5, pp 226-229, issn 0018-5043Article

Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestatHOTTA, N; KAWAMORI, R; ATSUMI, Y et al.Diabetic medicine. 2008, Vol 25, Num 7, pp 818-825, issn 0742-3071, 8 p.Article

Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells. Effect of antidiabetic medicinesOMI, Hitoshi; OKAYAMA, Naotsuka; SHIMIZU, Manabu et al.Journal of diabetes and its complications. 2002, Vol 16, Num 3, pp 201-208, issn 1056-8727Article

Current progress in clinical trials of aldose reductase inhibitors in JapanHOTTA, N; KAKUTA, H; ANDO, F et al.Experimental eye research. 1990, Vol 50, Num 6, pp 625-628, issn 0014-4835, 4 p.Article

Effects of high glucose concentrations and epalrestat on sorbital and myo-inositol metabolism in cultured rabbit aortic smooth muscle cellsSAKAKIBARA, F; HOTTA, N; KOH, N et al.Diabetes (New York, NY). 1993, Vol 42, Num 11, pp 1594-1600, issn 0012-1797Article

Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitusUCHIDA, K; KIGOSHI, T; NAKANO, S et al.Clinical therapeutics. 1995, Vol 17, Num 3, pp 460-466, issn 0149-2918Article

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study : Diabetes IIGOTO, Y; HOTTA, N; SHIGETA, Y et al.Biomedicine & pharmacotherapy. 1995, Vol 49, Num 6, pp 269-277, issn 0753-3322Article